AMAG Pharmaceuticals (AMAG) $14.98, is a biopharmaceutical company, engaged in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Its principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company is pursuing marketing applications in the European Union, Canada, and Switzerland for Feraheme for the treatment of IDA in CKD patients.
AMAG Investor Highlights
Announced that it's drug Feraheme achieved the predefined criteria for non-inferiority on both primary efficacy endpoints in Phase III.
As of December 31, 2011, the company’s cash, cash equivalents and investments totaled approximately $230 million.
Total revenues for the year ended December 31, 2011 were $61.2 million, of which $52.1 million were net product revenues from Feraheme.
AMAG is continuing to work with Jefferies & Company, Inc. to identify and evaluate various strategies to enhance stockholder value, including a potential sale of the company, and leverage AMAG’s core assets.
AMAG has no debt.
Flotek Industries (FTK) $11.04, together with its subsidiaries, develops and supplies drilling and production related products and services to the energy and mining industries in the United States and internationally. The company operates in three segments: Chemicals, Drilling, and Artificial Lift.
The Chemicals segment designs, develops, manufactures, packages, and markets specialty chemicals used by oilfield service companies in oil and natural gas well drilling, cementing, stimulation, and production activities. This segment also designs, operates, and manages automated bulk material handling and loading facilities for oilfield service companies that handle oilfield products, including sand and other materials for well-fracturing operations, dry cement and additives for oil and natural gas well cementing, and supply materials used in oilfield operations.
The Drilling segment manufactures, sells, rents, and inspects specialized equipment for use in drilling, completion, production, and workover activities. Its rental tools include stabilizers, drill collars, reamers, wipers, jars, shock subs, wireless survey, and measurement while drilling tools, and mud-motors; and equipment comprises mining equipment, centralizers, and drill bits. This segments downhole drilling tools are used in the oilfield, mining, water-well, and industrial drilling activities.
The Artificial Lift segment manufactures and markets artificial lift equipment, such as the Petrovalve line of rod pump components, electric submersible pumps, gas separators, valves, and services to support coal bed methane production activities. The company sells its products directly and through third party agents to integrated oil and natural gas companies, independent oil and natural gas companies, pressure pumping service companies, and state-owned national oil companies.
FTK Investor Highlights
Announced revenue for the year ended December 31, 2011 of $258.8 million, an increase of $111.8 million, or 76%, compared to $147.0 million for the same period in 2010.
For the year ended December 31, 2011 the Company posted net income attributable to common shareholders of $26.5 million or $0.56 per share (diluted).
For the three months ended December 31, 2011, Flotek posted revenue of $74.9 million, an increase of $27.4 million, or 57.8%, compared to $47.5 million in the same period of 2010. Revenue in all three business segments improved during the fourth quarter when compared to the year ago period.
As of December 31, 2011, the Company's cash balance was $46.7 million, the Company reduced its debt by nearly 50%, to $70.5 million, excluding capital leases. Announced that it has completed an initial expansion of its Marlow, Oklahoma chemical production facility.
SMTC Corporation (SMTX) $3.31, is a mid-size provider of end-to-end electronics manufacturing services (EMS) including PCBA production, systems integration and comprehensive testing services, enclosure fabrication, as well as product design, sustaining engineering and supply chain management services. SMTC facilities span a broad footprint in the United States, Canada, and Mexico, and a partnering relationship in China, with more than 1,800 full-time employees. SMTC services extend over the entire electronic product life cycle from the development and introduction of new products through to the growth, maturity and end-of-life phases.
SMTC offers fully integrated contract manufacturing services with a distinctive approach to global original equipment manufacturers (OEMs) and emerging technology companies primarily within industrial, computing and communication market segments.
SMTX Investor Highlights
Announced revenue for the latest quarter was $71.1 million and increased sharply over third quarter revenues due to increased demand from both existing and new customers, as well as from the recently completed ZF acquisition. Gross margins increased from 8.7% to 10.9%.
Fourth quarter results of $4.3 million in adjusted EBITDA, $2.9 million in net income, $5.5 million operating cash flow, and $0.18 EPS.
Presents Q1 guidance of $72-$74 million of revenue, $4.3 to $4.5 million of adjusted EBITDA, and $0.17-$0.19 adjusted EPS.
Raises 2012 guidance to $14-16 million adjusted EBITDA, $250-270 million revenue, and $0.53 - $0.65 EPS, up from $13-15 million adjusted EBITDA, $240-260 million revenue, and $0.47 - $0.59 EPS prior guidance.
Announced it has received the 2012 Global Electronics Manufacturing Service (EMS) Product Quality Leadership Award from Frost & Sullivan.
Announced the completion of a signed contract agreement to manufacture Alstom's leading edge transportation technology systems and products.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been been compensated by any of the above mentioned companies and holds no positions at this time.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.